CHANGES IN SEROTYPE DISTRIBUTION OF INVASIVE PNEUMOCOCCAL DISEASE IN COLOMBIA AFTER MASS VACCINATION WITH PCV10
- German Camacho Moreno, Colombia
- Aura L. Leal Castro, Colombia
- Jaime A. Patiño Niño, Colombia
- Vivian Marcela Moreno Mejia, Colombia
- Ivan F. Gutierrez Tobar, Colombia
- Cristina Mariño, Colombia
- Sandra Beltran, Colombia
- Martha I. Alvarez-Olmos, Colombia
- Rocio Barrero Barreto, Colombia
- Juan P. Rojas, Colombia
- Fabio Espinosa, Colombia
- Catalina Arango, Colombia
- Maria A. Suarez, Colombia
- Monica Trujillo, Colombia
- Eduardo López, Colombia
- Pio López, Colombia
- Wilfrido Coronell, Colombia
- Hernando Pinzon, Colombia
- Nicolas Ramos, Colombia
- Anita Montañez, Colombia
Invasive Pneumococcal Disease(IPD) causes high morbidity and mortality in children under 5 years. Colombia implemented PCV10 in 2012, and Neumocolombia network monitors IPD in pediatric patients throughout the country.
Ambispective case series study conducted in pediatric patients with IPD admitted to 10 hospitals of Bogotá (2008-2019), and 4 hospitals of Cali, 2 of Medellín, and 1 of Cartagena (2017-2019). Preliminary data on serotype(Spn) and resistance were obtained.
651 patients were included. Serotyping was obtained in 417(64%); the most frequent serotypes were 19A(26.8%), 14(15.5%), 3(10.3%); and 1(10%). IPD prevalence in serotype 14 decreased from 35.3% (41/116) in 2008-2011 to 6.4% (6/93) in 2012-2014 and to 8.9% (18/202) in 2015-2019. Serotype 1 prevalence decreased from 18.12% (21/116) in 2008-2011, to 19.3%(18/93) in 2012-2014 and to 1.4%(3/202) in 2015-2019. Spn19A increased from 4.3%(5/116) in 2008-2011 to 10.7%(10/93) in 2012-2014 and to 56%(112/202) in 2015-2019. Spn3 increased from 3.4%(4/116) in 2008-2011 to 11.8%(11/93) in 2012-2014, and to 13.8%(28/202) in 2015-2019.
The prevalence of serotypes 14 and 1, included in PCV10, decreased, while serotypes 19A and 3 increased. These findings are relevant for IPD epidemiology, and, according to the WHO, they should promote a change in the immunization schedule with a vaccine against these serotypes.